On January 19, 2021 Suzhou Sinovent reported that it completed a pre-IPO financing of at least $30 million in a round led by Oceanpine Healthcare Fund (Press release, Sinovent, JAN 19, 2021, View Source [SID1234574119]). Founded in 2016, Sinovent is a global biopharma that has 12 biologic products in development, five in clinical trials and another three molecules preparing to file INDs in China. Its lead program is a Wnt pathway porcupine inhibitor aimed at cancers of the digestive system, including colon cancer, esophageal cancer and gastric cancer. In August of last year, Sinovent completed a $145 million C round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!